Imbruvica

DRUG2 trials

Sponsors

Rabin Medical Center, Janssen Research & Development, LLC

Conditions

Central Nervous System LymphomaHealthy

Phase 1

Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA Capsule

CompletedNCT02877225

Janssen Research & Development, LLCHealthy

Start: 2016-08-29End: 2016-11-11Updated: 2017-03-10

Phase 2

Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma

Rabin Medical CenterCentral Nervous System Lymphoma

Start: 2016-10-31End: 2023-12-31Target: 30Updated: 2022-05-10